Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:ATYR)

1.060 +0.040 (+3.92%)
Streaming Delayed Price Updated: 2:43 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,531,107
Open 1.010
Bid (Size) 1.050 (48)
Ask (Size) 1.060 (154)
Prev. Close 1.020
Today's Range 0.9952 - 1.065
52wk Range 0.6816 - 7.290
Shares Outstanding 54,291,754
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ATYR
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-72.9%
-72.9%
1 Month
+1.0%
+1.0%
3 Month
-81.4%
-81.4%
6 Month
-67.7%
-67.7%
1 Year
-67.5%
-67.5%

More News

Read More
Class Action Filed Against aTyr Pharma, Inc. (ATYR) - December 8, 2025 Deadline to Join - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against aTyr Pharma, Inc. (ATYR) - December 8, 2025 Deadline to Join - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Law Offices of Frank R. Cruz Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
Law Offices of Howard G. Smith Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
From Pomerantz LLP
Via GlobeNewswire
Levi & Korsinsky Notifies Shareholders of aTyr Pharma, Inc. (ATYR) of a Class Action Lawsuit and an Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Notifies Shareholders of aTyr Pharma, Inc. (ATYR) of a Class Action Lawsuit and an Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
Securities Fraud Investigation Into aTyr Pharma Inc. (ATYR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Faruqi & Faruqi Reminds ATyr Pharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 9, 2025 - ATYR
From Faruqi & Faruqi LLP
Via GlobeNewswire
Securities Fraud Investigation Into aTyr Pharma Inc. (ATYR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
From Hagens Berman
Via Business Wire
ATYR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against aTyr Pharma, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi, LLP
Via Business Wire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
From The Rosen Law Firm PA
Via GlobeNewswire
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.
From Robbins LLP
Via GlobeNewswire
aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
From DJS Law Group
Via Business Wire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
From Pomerantz LLP
Via GlobeNewswire
Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs
Via Benzinga
Top 3 Health Care Stocks That May Explode In September
Via Benzinga

Frequently Asked Questions

Is aTyr Pharma, Inc. - Common Stock publicly traded?
Yes, aTyr Pharma, Inc. - Common Stock is publicly traded.
What exchange does aTyr Pharma, Inc. - Common Stock trade on?
aTyr Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for aTyr Pharma, Inc. - Common Stock?
The ticker symbol for aTyr Pharma, Inc. - Common Stock is ATYR on the Nasdaq Stock Market
What is the current price of aTyr Pharma, Inc. - Common Stock?
The current price of aTyr Pharma, Inc. - Common Stock is 1.060
When was aTyr Pharma, Inc. - Common Stock last traded?
The last trade of aTyr Pharma, Inc. - Common Stock was at 10/21/25 02:43 PM ET
What is the market capitalization of aTyr Pharma, Inc. - Common Stock?
The market capitalization of aTyr Pharma, Inc. - Common Stock is 57.55M
How many shares of aTyr Pharma, Inc. - Common Stock are outstanding?
aTyr Pharma, Inc. - Common Stock has 58M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.